# Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab

> **NCT03472885** · PHASE2 · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 12 (actual)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria (PNH)

## Interventions

- **DRUG:** Danicopan
- **DRUG:** Eculizumab

## Key facts

- **NCT ID:** NCT03472885
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-08
- **Primary completion:** 2019-09-20
- **Final completion:** 2023-01-05
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03472885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03472885, "Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03472885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*